Immunoassay Market

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027

Report Code: MD 4751 Aug, 2022, by marketsandmarkets.com

[430 Pages Report] The global immunoassay market is projected to reach 49.6 billion by 2027, from 40.2 billion in 2022, at a CAGR of 4.3%. Market growth is driven by the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, and growth in the biotechnology and biopharmaceutical industries.

Immunoassay Market

To know about the assumptions considered for the study, Request for Free Sample Report

Immunoassay Market Dynamics

Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis

The burden of chronic diseases, along with the massive infection rate and the COVID-19 pandemic, has necessitated the use of immune-diagnostic assays for containment and management. Immunoassay tests are considered an essential diagnostic tool that offers reliable and low-cost detection of pathogens or target molecules. These tests are used to diagnose both highly prevalent and chronic diseases.

On a global scale, immunoassays have become the frontline diagnostics for detecting several pathogens and pathophysiological conditions. The increasing demand for the early-stage diagnosis of disease conditions using immunoassay products is another major factor driving the market growth.

Globally, the number of diabetics is expected to grow from 643 million in 2030 to 783 million by 2045. Diabetes resulted in 6.7 million deaths worldwide in 2021, while 541 million people are estimated to be at risk of developing diabetes (Source: International Diabetes Federation).

The WHO underlined the global concern of HIV, which has claimed over 33 million lives; an estimated 38 million people have HIV infections. Similarly, The International Agency for Research on Cancer and GLOBOCAN estimated 19.3 million new cases of cancer and 10.0 million deaths in 2020. Breast cancer dominates this estimate with 2.3 million new cases, followed by lung, colorectal, prostate, and stomach cancer.

Advancements in systems and technologies

Key players and researchers have several advanced, reliable, and economic immunoassay platforms for disease diagnostics. Automated systems offer flexibility in scale-up, massive sampling volume, faster processing, vast storage, and high efficacy required for COVID-19 diagnosis and management. Recent developments in this market include:

  • In September 2021, Thermo Fisher Scientific, Inc. (US) launched its fully automated analyzers, Thermo Scientific Gallery Enzyme Master and Thermo Scientific Gallery Plus Enzyme Master, which are specifically designed for enzyme assay applications.
  • In May 2021, Beckman Coulter (US) launched its fully automated and qualitative COVID-19 immunoassay, Access SARS-CoV-2 IgG (1st IS). The immunoassay is a fully quantitative lab-based Immunoglobulin G (IgG) serology test intended to measure the number of antibodies against the virus that causes COVID-19.
  • In February 2021, F. Hoffmann-La Roche (Switzerland) launched the SARS-CoV-2 Rapid Antigen Test Nasal with patient self-collection.

Other important areas are rapid immunoassays, decentralized and near-patient point-of-care (POC) assays, and lateral flow assays that enable assays to be accessed by patients without sophisticated instruments. Nanozymes—enzyme-like nanomaterial mimicking catalase, oxidase, and peroxidase—are also emerging technologies utilized as alternatives to natural enzymes used in ELISA and biosensing.

Technical hurdles of immunoassay kits a key restraining factor limiting the growth of market

There are several disadvantages associated with immunoassays. Cross-reactivity has been a constant element challenging the reliability and specificity of the immunoassays. Antibodies bind with the structural analogs of the target antibody/analyte in immunoassays. Other issues involve the need for high sample volumes for detection, complex workflows, unsuitability for high-throughput screening analysis (ELISA), and reagent instability.

The routine colorimetric readout ELISA is not considered suitable for low-concentration analytes or target molecules. Immunoassays are not considered specific assays for the diagnosis of viral RNA sequences. They have been observed to have issues associated with detecting certain biomolecules such as non-specific IgM, rheumatoid factor, and interferons.

Immunoassays are also associated with false negatives during the early stage of the infection. This inaccurate sensitivity is a challenge among the mildly symptomatic to asymptomatic who have a low titer of antibodies in response to the coronavirus infection.

Immunoassay Market Ecosystem

Immunoassay Market Ecosystem

“In 2021, kits reagents segment accounted for the largest share of the immunoassay market, by product”

The global immunoassay market is segmented into reagents kits and analyzers based on product. Market growth is largely driven by the high consumption and frequent purchases of reagents kits coupled with the rise in the number of immunoassay tests performed across the globe.

In 2021, ELISA accounted for the largest share in the immunoassay market, by technology”

The global market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. ELISA accounted for the largest share of the global market in 2021. The large share of this technology segment can primarily be attributed to the increasing use of ELISA tests in cancer diagnosis, infectious diseases detection, and therapeutic drug level monitoring.

In 2021, blood specimen segment accounted for the largest share in the immunoassay market, by specimen”

Based on specimens, the global market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens accounted for the largest share of the global market, primarily due to the rising incidence of chronic and infectious diseases.

“In 2021, infectious diseases segment accounted for the largest share of the immunoassay market, by application”

The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. Rising prevalence of infectious diseases and increase in the number of products launches catering to infectious disease diagnosis to drive growth of the segment.

In 2021, hospitals clinics accounted for the largest share in the immunoassay market, by end user”

The global market is segmented into hospitals clinics, clinical laboratories, pharmaceutical biotechnology companies and CROs, blood banks, research academic laboratories, and home care settings. Hospitals clinics accounted for the largest share of the global market by end user.

“In 2021, North America accounted for the largest share of the immunoassay market ”

The global global market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Rest of the World, and Latin America. North America accounted for the largest share of the global market in 2021. Factors such as the the availability of government funds, the growing use of immunoassays in clinical diagnostics, and the presence of key players in the region are contributing to the large share of this regional segment.

Immunoassay Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The immunoassay market is dominated by players such as Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD Billion)

Segments covered

Product, Technology, Specimen, Application, End User, and region

Geographies covered

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America

Companies covered

Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), PerkinElmer (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio- Rad Laboratories (US), Quidel Corporation (US), Ortho Clinical Diagnostics Holdings (US), bioMιrieux (France), QIAGEN (Netherlands), Sysmex Corporation (Japan), Agilent Technologies (US), Mindray Medical International Company (China), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical (Germany), Sera Care (US), Epitope Diagnostics (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), and InBios International (US).

This report categorizes the immunoassay market into the following segments and subsegments:

By Product

  • Reagents & Kits
    • ELISA Reagents & Kits
    • Rapid Test Reagent & Kits
    • ELISpot Reagent & Kits
    • Western Blot Reagent & Kits
    • Other Reagent & Kits
  • Analyzers
    • By Type
      • Open-ended Systems
      • Closed-ended Systems
    • By Purchase Mode
      • Rental Purchase
      • Outright Purchase

By Technology

  • ELISA
    • By Generation
      • Third-generation & Above
      • Second-generation & Belo
  • Rapid Tests
  • ELISpot
  • Western Blotting
  • Radioimmunoassays
  • Other Technologies

By Specimen

  • Blood
  • Saliva
  • Urine
  • Other Specimens

By Application

  • Infectious Diseases
  • Endocrinology
  • Oncology
  • Bone & Mineral Disorders
  • Cardiology
  • Blood Screening
  • Autoimmune Disorders
  • Allergy Diagnostics
  • Toxicology
  • Newborn Screening
  • Other Applications

By End User

  • Hospitals & Clinics
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies and CROs
  • Blood Banks
  • Research & Academic Laboratories
  • Home Care Settings

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In June 2022, Roche received Emergency Use Authorization from the FDA for the Cobas SARS-CoV- 2 Duo for use on the fully automated Cobas 6800/8800 Systems.
  • In July 2021, Beckman Coulter entered into an agreement with Quidel Corporation to gain rights for the manufacturing, distribution, and sales of a BNP assay by Quidel for Beckman Coulter analyzers.
  • In December 2020, Abbott received US FDA EUA for its BinaxNOW COVID-19 Ag Card Rapid Test.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1  INTRODUCTION (Page No. - 44)
    1.1  STUDY OBJECTIVES
    1.2  MARKET DEFINITION 
          1.2.1  INCLUSIONS & EXCLUSIONS
    1.3  MARKET SCOPE
           FIGURE  1 IMMUNOASSAY MARKET
           1.3.1  YEARS CONSIDERED
    1.4  CURRENCY CONSIDERED
    1.5  STAKEHOLDERS
    1.6  SUMMARY OF CHANGES

2  RESEARCH METHODOLOGY (Page No. - 48)
   2.1  RESEARCH DATA 
          FIGURE  2  RESEARCH DESIGN
          2.1.1  SECONDARY DATA
                  2.1.1.1  SECONDARY SOURCES
          2.1.2  PRIMARY DATA
                    2.1.2.1  KEY DATA FROM PRIMARY SOURCES
                    2.1.2.2  KEY INDUSTRY INSIGHTS
                                 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2  MARKET SIZE ESTIMATION
           2.2.1  BOTTOM-UP APPROACH
                     FIGURE 5  MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                     FIGURE 6  MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
                     FIGURE 7  CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    2.3  MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4  MARKET SHARE ANALYSIS
    2.5  STUDY ASSUMPTIONS
    2.6  RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
    2.7  LIMITATIONS
            2.7.1  METHODOLOGY-RELATED LIMITATIONS
            2.7.2  SCOPE-RELATED LIMITATIONS
    2.8  GROWTH RATE ASSUMPTIONS

3  EXECUTIVE SUMMARY (Page No. - 59)
    FIGURE 9  IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
    FIGURE 10  GLOBAL MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)
    FIGURE 11  GLOBAL MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION)
    FIGURE 12  GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)
    FIGURE 13  GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)
    FIGURE 14  GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

4  PREMIUM INSIGHTS (Page No. - 65)
    4.1  IMMUNOASSAY MARKET OVERVIEW
          FIGURE 15  RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH
    4.2  NORTH AMERICA: MARKET, BY PRODUCT & COUNTRY (2021)
           FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
    4.3  GLOBAL MARKET: GEOGRAPHICAL SNAPSHOT
           FIGURE 17  CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
    4.4  GLOBAL MARKET: GEOGRAPHIC MIX
           FIGURE 18  APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5  GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 19  DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5  MARKET OVERVIEW (Page No. - 70)
    5.1  INTRODUCTION
    5.2  MARKET DYNAMICS
           FIGURE 20 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1  DRIVERS
                     5.2.1.1  INCREASING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES AND GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS
                                 FIGURE 21  INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
                                 TABLE 2  GLOBAL INCIDENCE OF INFECTIOUS DISEASES
                                 5.2.1.1.1  INCREASING USE OF IMMUNOASSAYS IN ONCOLOGY
                                                 TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020
                                                 TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020
                                  5.2.1.1.2 IMMUNOASSAYS FOR COVID-19 AND OTHER VIRAL DIAGNOSTICS
                                  5.2.1.1.3 IMMUNOASSAYS IN DRUG DETECTION AND OTHER DIAGNOSTIC APPLICATIONS
                                                 TABLE 5  DETECTION OF DRUGS BY URINE TESTING
                                  5.2.1.1.4  GROWING GERIATRIC POPULATION
                                                  FIGURE 22  GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
                     5.2.1.2  ADVANCEMENTS IN SYSTEMS AND TECHNOLOGIES
                     5.2.1.3  GROWTH IN BIOTECHNOLOGY AND BIOPHARMACEUTICAL INDUSTRIES
                     5.2.1.4  INCREASING ADOPTION OF IMMUNOASSAY-BASED POC TESTING AND RAPID TESTING
                                  TABLE 6  RECENT WAIVERS OF MARKET PRODUCTS
                     5.2.1.5  SUPPORTIVE GOVERNMENT POLICIES
                     5.2.1.6  INCREASING DRUG AND ALCOHOL ABUSE AND STRINGENT LAWS MANDATING DRUG AND ALCOHOL TESTING
            5.2.2  RESTRAINTS
                     5.2.2.1 STRINGENT REQUIREMENTS FOR APPROVAL OF IMMUNOASSAY INSTRUMENTS AND CONSUMABLES
                     5.2.2.2 TECHNICAL HURDLES OF IMMUNOASSAY KITS
            5.2.3  OPPORTUNITIES
                      5.2.3.1  GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
                      5.2.3.2  IMPORTANCE OF COMPANION DIAGNOSTICS
                                   TABLE 7  COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED
                      5.2.3.3  DEVELOPMENT OF CONDITION-SPECIFIC BIOMARKERS AND TESTS
                                   TABLE 8  NEW TESTS LAUNCHED BY KEY PLAYERS
                       5.2.3.4  INTEGRATION OF MICROFLUIDICS IN IMMUNOASSAYS
                                    TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS
                        5.2.3.5  IMPROVING IMMUNOASSAY DIAGNOSTIC TECHNOLOGIES
              5.2.4  CHALLENGES
                        5.2.4.1  DESIGN CHALLENGES, COMPLEXITIES, AND QUALITY OF ANTIBODIES
                        5.2.4.2  DEARTH OF SKILLED PROFESSIONALS
                        5.2.4.3  UNFAVORABLE REIMBURSEMENT SCENARIO
                        5.2.4.4  FINANCIAL HURDLES FACED BY PHYSICIANS
    5.3  REGULATORY OVERVIEW
           5.3.1  US
                    TABLE 10  US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
                    FIGURE 23  US: REGULATORY PROCESS FOR IVD DEVICES
            5.3.2  CANADA
                      FIGURE 24  CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
            5.3.3  EUROPE
                      TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
            5.3.4  JAPAN
                      5.3.4.1  JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                                   TABLE 12  JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
                                   TABLE 13  JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
            5.3.5  CHINA
                      TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
            5.3.6  INDIA
                      5.3.6.1  INDIA: REGULATORY PROCESS FOR IVD DEVICES
            5.3.7  INDONESIA
                      TABLE 15  INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
            5.3.8   RUSSIA
                       TABLE  16 RUSSIA: CLASSIFICATION OF IVD DEVICES
            5.3.9   SAUDI ARABIA
                       TABLE 17  SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
            5.3.10 MEXICO
                       5.3.10.1  MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                                      TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
            5.3.11  BRAZIL
                        5.3.11.1  BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
            5.3.12  SOUTH KOREA
                        TABLE 19  SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
            5.3.13  MIDDLE EAST
            5.3.14  AFRICA
     5.4  TECHNOLOGY ANALYSIS
            TABLE 20  CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
            TABLE 21  RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
     5.5  TRADE ANALYSIS
            5.5.1  TRADE ANALYSIS FOR IMMUNOASSAYS
                      TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION)
                      TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION)
     5.6  PATENT ANALYSIS
     5.7  VALUE CHAIN ANALYSIS
             FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
     5.8  SUPPLY CHAIN ANALYSIS
            FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
     5.9  ECOSYSTEM ANALYSIS OF GLOBAL MARKET
            FIGURE 27 ECOSYSTEM ANALYSIS OF GLOBAL MARKET
            5.9.1  ROLE IN ECOSYSTEM
            5.9.2  KEY PLAYERS OPERATING IN GLOBAL MARKET
     5.10  PORTER’S FIVE FORCES ANALYSIS
             TABLE 24  HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
             5.10.1  DEGREE OF COMPETITION
             5.10.2  BARGAINING POWER OF SUPPLIERS
             5.10.3  BARGAINING POWER OF BUYERS
             5.10.4  THREAT FROM SUBSTITUTES
             5.10.5  THREAT FROM NEW ENTRANTS
    5.11  KEY CONFERENCES & EVENTS IN 2022 
             TABLE 25 LIST OF CONFERENCES & EVENTS
     5.12  PRICING ANALYSIS
              TABLE 26  IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS
     5.13  KEY STAKEHOLDERS & BUYING CRITERIA
              5.13.1  KEY STAKEHOLDERS IN BUYING PROCESS
                          FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
                          TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
              5.13.2   BUYING CRITERIA
                           FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
                          TABLE 28 KEY BUYING CRITERIA, BY END USER
     5.14  TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
     5.15  SCENARIO-BASED MARKET ASSESSMENT
              5.15.1  IMMUNOASSAY MARKET FORECAST
                          FIGURE 30  PESSIMISTIC SCENARIO
                          FIGURE 31  OPTIMISTIC SCENARIO
                          FIGURE 32  REALISTIC SCENARIO

6  IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 113)
    6.1  INTRODUCTION
           TABLE 29  GLOBAL MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2  REAGENTS & KITS
           TABLE 30  IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET
           TABLE 31  IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
           TABLE 32  IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
           6.2.1  ELISA REAGENTS & KITS
                     6.2.1.1  WIDE USAGE IN BASIC RESEARCH AND HIGH-THROUGHPUT SCREENING
                                  TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
            6.2.2  RAPID TEST REAGENTS & KITS
                      6.2.2.1  HIGH DEMAND FOR RAPID TEST REAGENTS & KITS IN REMOTE AREAS TO DRIVE GROWTH
                                   TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
            6.2.3  ELISPOT REAGENTS & KITS
                      6.2.3.1  HIGH SENSITIVITY, FUNCTIONALITY, AND ADAPTABILITY OF ELISPOT TECHNOLOGY TO DRIVE DEMAND
                                   TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
            6.2.4  WESTERN BLOT REAGENTS & KITS
                      6.2.4.1  GOLD STANDARD FOR RESULT CONFIRMATION PROMOTES WESTERN BLOTTING REAGENTS & KITS
                                   TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
            6.2.5   OTHER REAGENTS & KITS
                     TABLE 37  OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3  ANALYZERS
           TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET
           TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
            6.3.1  IMMUNOASSAY ANALYZERS MARKET, BY TYPE
                     TABLE 40  IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                     6.3.1.1  OPEN-ENDED SYSTEMS
                                  6.3.1.1.1 FLEXIBILITY AND WIDE AVAILABILITY MAKE OPEN-ENDED SYSTEMS POPULAR AMONG USERS
                                              41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
                      6.3.1.2  CLOSED-ENDED SYSTEMS
                                    6.3.1.2.1  HIGH PRECISION AND AUTOMATION ARE KEY FEATURES OF CLOSED-ENDED SYSTEMS
                                                    TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
             6.3.2  IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
                       TABLE 43  IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                      6.3.2.1  RENTAL PURCHASE
                                   6.3.2.1.1  CONVENIENCE AND LACK OF LIABILITY FOR END USERS DRIVE PREFERENCE FOR DEVICE RENTAL
                                                   TABLE 44  RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
                      6.3.2.2  OUTRIGHT PURCHASE
                                   6.3.2.2.1  OUTRIGHT PURCHASE IS FAVORED BY GOVERNMENT ORGANIZATIONS, BIG COMPANIES, AND CROS
                                                   TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)

7  IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 129)
     7.1  INTRODUCTION
           TABLE 46 GLOBAL MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
     7.2  ELISA
           TABLE 47  KEY ELISA SYSTEMS AVAILABLE IN MARKET
           TABLE 48  GLOBAL MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION)
            7.2.1  ELISA MARKET, BY GENERATION
                    TABLE 49  GLOBAL MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                    7.2.1.1  THIRD-GENERATION & ABOVE
                               7.2.1.1.1 THIRD- & FOURTH-GEN ELISA SHOW HIGH SPECIFICITY AND ACCURACY
                                              TABLE 50  THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
                    7.2.1.2  SECOND-GENERATION & BELOW
                               7.2.1.2.1  COST-EFFECTIVENESS OF FIRST- AND SECOND-GENERATION TESTS SUPPORTS THEIR USE
                                              TABLE 51  SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.2  ELISA MARKET, BY TYPE
                    TABLE 52  GLOBAL MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                    7.2.2.1  CLIA
                                 7.2.2.1.1  CLIA HOLDS LARGEST SHARE OF ELISA MARKET, BY TYPE
                                                  TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION)
                     7.2.2.2  IFA
                                  7.2.2.2.1  IFA IS USED TO DIAGNOSE ANTIBODIES AGAINST INFECTIOUS PATHOGENS
                                                  TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION)
                      7.2.2.3  COLORIMETRIC IMMUNOASSAYS
                                   7.2.2.3.1  INTRODUCTION OF ADVANCED TECHNIQUES WILL SUPPORT MARKET GROWTH
                                                   TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
     7.3  RAPID TESTS
            7.3.1  WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH
                    TABLE 56  KEY RAPID TESTS AVAILABLE IN MARKET
                    TABLE 57  IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION)
     7.4  WESTERN BLOTTING
            7.4.1  WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH
                    TABLE 58  WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
                    TABLE 59  GLOBAL MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION)
     7.5  RADIOIMMUNOASSAYS
            7.5.1  HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH
                    TABLE 60  GLOBAL MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)
     7.6  ELISPOT
            7.6.1  HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS
                    TABLE 61  GLOBAL MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION)
     7.7  OTHER TECHNOLOGIES
            TABLE 62  GLOBAL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

8  IMMUNOASSAY MARKET, BY SPECIMEN (Page No. - 144)
    8.1  INTRODUCTION
           TABLE 63  GLOBAL MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
    8.2  BLOOD
           8.2.1  HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH
                     TABLE 64  GLOBAL MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
    8.3  SALIVA
            8.3.1  CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH
                      TABLE 65 GLOBAL MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
    8.4  URINE
            8.4.1  USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS
                      TABLE 66 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
    8.5  OTHER SPECIMENS
           TABLE 67  GLOBAL MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION)

9  IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 150)
     9.1  INTRODUCTION
            TABLE 68 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
     9.2  INFECTIOUS DISEASES
            9.2.1  RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                      TABLE 69 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
     9.3  ENDOCRINOLOGY
            9.3.1  RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS
                      TABLE 70 GLOBAL MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.4  CARDIOLOGY
            9.4.1  HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH
                      TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS
                      TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.5  AUTOIMMUNE DISORDERS
            9.5.1  RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH
                      TABLE 73 GLOBAL MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION)
     9.6  ALLERGY DIAGNOSTICS
            9.6.1  GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS
                      TABLE 74 GLOBAL MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
     9.7  ONCOLOGY
            9.7.1  RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH
                      TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                      TABLE 76 GLOBAL MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.8  BONE & MINERAL DISORDERS
            9.8.1  HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
                      TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS
                      TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
     9.9  TOXICOLOGY
            9.9.1  DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY
                      TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING
                      TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS
                      TABLE 81 GLOBAL MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.10  BLOOD SCREENING
              9.10.1  RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS
                          TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.11 NEWBORN SCREENING
             9.11.1  IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR
                        TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING
                        TABLE 84 GLOBAL MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
     9.12  OTHER APPLICATIONS
              TABLE 85 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)

10  IMMUNOASSAY MARKET, BY END USER (Page No. - 167)
      10.1  INTRODUCTION
               TABLE 86 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
      10.2  HOSPITALS & CLINICS
              10.2.1  GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH
                          TABLE 87 GLOBAL MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
      10.3  CLINICAL LABORATORIES
               10.3.1  RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS
                           TABLE 88 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
      10.4  PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
               10.4.1  GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY
                           TABLE 89 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION)
      10.5  HOME CARE SETTINGS
               10.5.1  RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH
                           TABLE 90 GLOBAL MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION)
      10.6  BLOOD BANKS
               10.6.1  RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING
                           TABLE 91 GLOBAL MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION)
      10.7  RESEARCH & ACADEMIC LABORATORIES
               10.7.1  RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH
                           TABLE 92 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)

11  IMMUNOASSAY MARKET, BY REGION (Page No. - 176)
      11.1 INTRODUCTION
              TABLE 93 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
      11.2 NORTH AMERICA
              FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
              TABLE 94 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
              TABLE 95 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
              TABLE 96 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 98 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
              TABLE 99 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
              TABLE 100 NORTH AMERICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
              TABLE 101 NORTH AMERICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 102 NORTH AMERICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
              TABLE 103 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
              TABLE 104 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.2.1 US
                         11.2.1.1 US HOLDS LARGEST SHARE IN NORTH AMERICAN MARKET
                                       TABLE 105 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                       TABLE 106 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 108 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                       TABLE 109 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                       TABLE 110 US: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                       TABLE 111 US: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 112 US: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                       TABLE 113 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                       TABLE 114 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.2.2  CANADA
                          11.2.2.1  INITIATIVES UNDERTAKEN BY GOVERNMENT BODIES TO SUPPORT GROWTH OF MARKET IN CANADA
                                         TABLE 115 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 116 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 118 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 119 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 120 CANADA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 121 CANADA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 122 CANADA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 123 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 124 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
      11.3  EUROPE
               TABLE 125  EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 126  EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
               TABLE 127  EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 128  EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 129  EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
               TABLE 130  EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 131  EUROPE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
              TABLE 132  EUROPE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 133  EUROPE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
              TABLE 134  EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
              TABLE 135  EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.1  GERMANY
                          11.3.1.1  GERMANY HOLDS LARGEST SHARE OF EU IMMUNOASSAY MARKET
                                         TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 137 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 139 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 140 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 141 GERMANY: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 142 GERMANY: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 143 GERMANY: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                          TABLE 144 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                          TABLE 145 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.2  ITALY
                         11.3.2.1  GROWING GERIATRIC POPULATION AND INCREASING SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
                                        TABLE 146  ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                        TABLE 147  ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 148  ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 149  ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                        TABLE 150  ITALY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                       TABLE 151  ITALY: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                       TABLE 152  ITALY: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 153  ITALY: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                       TABLE 154  ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                       TABLE 155  ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.3  FRANCE
                          11.3.3.1  RISING USE OF POC TESTING AND FAVORABLE REIMBURSEMENT POLICIES MAKE FRANCE A LUCRATIVE MARKET
                                         TABLE 156  FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 157  FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 158  FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 159  FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 160  FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 161  FRANCE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 162  FRANCE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 163  FRANCE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 164  FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 165  FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.4  SPAIN
                          11.3.4.1  INCREASING ADOPTION OF TECHNOLOGICALLY ADVANCED IMMUNOASSAY SYSTEMS MAKES SPAIN A RELATIVELY LARGE MARKET
                                         TABLE 166  SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 167  SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 168  SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 169  SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 170 SPAIN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 171  SPAIN: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 172  SPAIN: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 173  SPAIN: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 174  SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 175  SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.5  UK
                          11.3.5.1  GOVERNMENT SUPPORT FOR DISEASE DIAGNOSTICS AND FAVORABLE INVESTMENT SCENARIO DRIVE MARKET IN UK
                                         TABLE 176  UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 177  UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 178  UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 179  UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 180  UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 181  UK: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 182  UK: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 183  UK: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                          TABLE 184  UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                          TABLE 185  UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.6  RUSSIA
                          11.3.6.1  LACK OF REIMBURSEMENT AND DELAYS IN APPROVAL MAY HINDER MARKET GROWTH
                                         TABLE 186  RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 187  RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 188  RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 189  RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 190  RUSSIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 191  RUSSIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 192  RUSSIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 193  RUSSIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 194  RUSSIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 195  RUSSIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.3.7  REST OF EUROPE
                          TABLE 196  REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                          TABLE 197  REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 198  REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 199  REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                          TABLE 200  REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                          TABLE 201  REST OF EUROPE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                          TABLE 202  REST OF EUROPE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 203  REST OF EUROPE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                          TABLE 204  REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                          TABLE 205  REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
      11.4  ASIA PACIFIC
               FIGURE 34  ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
               TABLE 206  ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 207  ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
               TABLE 208  ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 209  ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 210  ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
               TABLE 211  ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 212  ASIA PACIFIC: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
               TABLE 213  ASIA PACIFIC: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 214  ASIA PACIFIC: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
               TABLE 215  ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 216  ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
               11.4.1 JAPAN
                          11.4.1.1  INVESTMENTS IN HEALTHCARE TECHNOLOGY AND RESEARCH TO SUPPORT GROWTH IN JAPAN
                                         TABLE 217  JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 218  JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 219  JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 220  JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 221  JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 222  JAPAN: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 223  JAPAN: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 224  JAPAN: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 225  JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                          TABLE 226  JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.4.2  CHINA
                          11.4.2.1  OPPORTUNITIES FOR GROWTH IN CHINA HAMPERED BY LONG PRODUCT APPROVAL AND REGISTRATION PROCESSES
                                         TABLE 227  CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 228  CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 229  CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 230  CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 231  CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 232  CHINA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 233  CHINA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 234  CHINA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 235  CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 236  CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.4.3  INDIA
                          11.4.3.1  GROWING MEDICAL TOURISM AND HEALTHCARE INFRASTRUCTURE WILL DRIVE USE OF IMMUNOASSAYS IN INDIA
                                         TABLE 237  INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 238  INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 239  INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 240  INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 241  INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 242  INDIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 243  INDIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 244  INDIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 245  INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 246  INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
               11.4.4  AUSTRALIA
                           11.4.4.1  GROWING DISEASE INCIDENCE AND TECHNOLOGICAL DEVELOPMENT DRIVE MARKET GROWTH
                                          TABLE 247  AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                          TABLE 248  AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE  249 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 250  AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                          TABLE 251  AUSTRALIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                          TABLE 252  AUSTRALIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                          TABLE 253  AUSTRALIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 254  AUSTRALIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                          TABLE 255  AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                          TABLE 256  AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.4.5  SOUTH KOREA
                          11.4.5.1  RISING HEALTHCARE SPENDING AND INVESTMENTS IN RESEARCH FUEL MARKET GROWTH
                                         TABLE 257 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                       TABLE 258 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 259 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 260 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                       TABLE 261 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                       TABLE 262 SOUTH KOREA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                       TABLE 263 SOUTH KOREA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                       TABLE 264 SOUTH KOREA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                       TABLE 265 SOUTH KOREA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                       TABLE 266 SOUTH KOREA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.4.6  INDONESIA
                          11.4.6.1  INDONESIA HAS BECOME A PROMISING MARKET AND GROWTH HOTSPOT FOR FOREIGN INVESTORS
                                         TABLE 267  INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                         TABLE 268  INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 269  INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 270  INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                         TABLE 271  INDONESIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                         TABLE 272  INDONESIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 273  INDONESIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 274  INDONESIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 275  INDONESIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 276 INDONESIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.4.7  REST OF ASIA PACIFIC
                          TABLE 277  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                          TABLE 278  REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 279  REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 280 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                          TABLE 281  REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                          TABLE 282  REST OF ASIA PACIFIC: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                          TABLE 283  REST OF ASIA PACIFIC: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 284  REST OF ASIA PACIFIC: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                          TABLE 285  REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                          TABLE 286  REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
      11.5  LATIN AMERICA
               TABLE 287  LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 288  LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
               TABLE 289  LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 290  LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 291  LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
               TABLE 292  LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 293  LATIN AMERICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
               TABLE 294  LATIN AMERICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 295  LATIN AMERICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
               TABLE 296  LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 297  LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
               11.5.1  BRAZIL
                           11.5.1.1  BRAZIL WAS LARGEST MARKET FOR IMMUNOASSAYS IN LATAM
                                          TABLE 298  BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS
                                          TABLE 299  BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                          TABLE 300  BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 301  BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 302  BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                          TABLE 303  BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                          TABLE 304  BRAZIL: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                          TABLE 305  BRAZIL: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 306  BRAZIL: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                          TABLE 307  BRAZIL: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                          TABLE 308  BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
               11.5.2  MEXICO
                           11.5.2.1  GROWING LAB CONSOLIDATION TO REDUCE NUMBER OF LABS IN MEXICO
                                          TABLE 309  MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                          TABLE 310  MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 311  MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                          TABLE 312  MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                                          TABLE 313  MEXICO: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                          TABLE 314  MEXICO: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                                         TABLE 315  MEXICO: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                                         TABLE 316  MEXICO: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                                         TABLE 317  MEXICO: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                         TABLE 318  MEXICO: MARKET, BY END USER, 2020–2027 (USD MILLION)
              11.5.3  REST OF LATIN AMERICA
                          TABLE 319  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                          TABLE 320  REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 321  REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 322  REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                          TABLE 323  REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                         TABLE 324  REST OF LATIN AMERICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                          TABLE 325  REST OF LATIN AMERICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 326  REST OF LATIN AMERICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                          TABLE 327  REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                          TABLE 328  REST OF LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
      11.6  MIDDLE EAST & AFRICA
               11.6.1  LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
                          TABLE 329  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                          TABLE 330  MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 331  MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 332  MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
                          TABLE 333  MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                          TABLE 334  MIDDLE EAST & AFRICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
                          TABLE 335  MIDDLE EAST & AFRICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                          TABLE 336  MIDDLE EAST & AFRICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
                          TABLE 337  MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                          TABLE 338  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)

12  COMPETITIVE LANDSCAPE (Page No. - 321)
      12.1  OVERVIEW
      12.2  KEY PLAYER STRATEGIES/RIGHT TO WIN
               12.2.1  OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS
      12.3  REVENUE ANALYSIS
               FIGURE 35  REVENUE ANALYSIS OF KEY PLAYERS
       12.4  MARKET SHARE ANALYSIS
                TABLE 339 GLOBAL MARKET: DEGREE OF COMPETITION
                FIGURE 36 MARKET SHARE ANALYSIS, 2021
      12.5   COMPANY EVALUATION MATRIX
                12.5.1  STARS
                12.5.2  EMERGING LEADERS
               12.5.3  PERVASIVE PLAYERS
               12.5.4  PARTICIPANTS
                           FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
      12.6  COMPANY EVALUATION QUADRANT (SMES/START-UPS)
               12.6.1  PROGRESSIVE COMPANIES
               12.6.2  STARTING BLOCKS
               12.6.3  RESPONSIVE COMPANIES
               12.6.4  DYNAMIC COMPANIES
                           FIGURE 38 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
      12.7  COMPANY FOOTPRINT ANALYSIS
               TABLE 340  COMPANY FOOTPRINT
               TABLE 341  COMPANY PRODUCT FOOTPRINT
               TABLE 342  COMPANY REGIONAL FOOTPRINT
      12.8  COMPETITIVE BENCHMARKING
                TABLE 343 IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
      12.9  COMPETITIVE SCENARIO
               12.9.1  PRODUCT LAUNCHES & APPROVALS
                           TABLE 344 GLOBAL MARKET: PRODUCT LAUNCHES & APPROVALS, 2019–2022
               12.9.2  DEALS
                           TABLE 345 IMMUNOASSAY MARKET: DEALS, 2019–2022
              12.9.3   OTHER DEVELOPMENTS
                           TABLE 346 GLOBAL MARKET: OTHER DEVELOPMENTS, 2019–2022

13  COMPANY PROFILES (Page No. - 335)
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
      13.1  MAJOR PLAYERS
              13.1.1  ABBOTT LABORATORIES
                         TABLE 347  ABBOTT LABORATORIES: BUSINESS OVERVIEW
                         FIGURE 39  ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
              13.1.2  ROCHE DIAGNOSTICS
                          TABLE 348  F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                          FIGURE 40  F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
              13.1.3  SIEMENS HEALTHINEERS AG
                          TABLE 349 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                          FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
               13.1.4  DANAHER CORPORATION
                           TABLE 350 DANAHER CORPORATION: BUSINESS OVERVIEW
                           FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
               13.1.5  THERMO FISHER SCIENTIFIC INC.
                           TABLE 351 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                           FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
               13.1.6  PERKINELMER, INC.
                          TABLE 352 PERKINELMER, INC.: BUSINESS OVERVIEW
                          FIGURE 44 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
               13.1.7  BECTON, DICKINSON AND COMPANY
                          TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                           FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
               13.1.8  DIASORIN S.P.A.
                          TABLE 354 DIASORIN S.P.A.: BUSINESS OVERVIEW
                          FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021)
               13.1.9  BIO-RAD LABORATORIES, INC.
                           TABLE 355 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                           FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
               13.1.10  QUIDEL CORPORATION
                             TABLE 356 QUIDEL CORPORATION: BUSINESS OVERVIEW
                             FIGURE 48 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
               13.1.11  ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
                             TABLE 357 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
                             FIGURE 49 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
              13.1.12  BIOMΙRIEUX
                            TABLE 358 BIOMΙRIEUX: BUSINESS OVERVIEW
                            FIGURE 50 BIOMΙRIEUX: COMPANY SNAPSHOT (2021)
              13.1.13  QIAGEN
                            TABLE 359 QIAGEN: BUSINESS OVERVIEW
                            FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2021)
              13.1.14  SYSMEX CORPORATION
                           TABLE 360 SYSMEX CORPORATION: BUSINESS OVERVIEW
                           FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
              13.1.15  AGILENT TECHNOLOGIES
                            TABLE 361 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
                            FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
              13.1.16  MINDRAY MEDICAL INTERNATIONAL COMPANY
                            TABLE 362 MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW
      13.2  OTHER PLAYERS
               13.2.1  MERCK KGAA
               13.2.2  MERIDIAN BIOSCIENCE
               13.2.3  BIO-TECHNE
               13.2.4  CELLABS
               13.2.5  ABNOVA CORPORATION
               13.2.6  J. MITRA & CO.
               13.2.7  TOSOH CORPORATION (TOSOH BIOSCIENCES)
               13.2.8  CELL SCIENCES
               13.2.9  ENZO BIOCHEM
               13.2.10  CREATIVE DIAGNOSTICS
               13.2.11  BOSTER BIOLOGICAL TECHNOLOGY
               13.2.12  ELABSCIENCE
               13.2.13  WAK-CHEMIE MEDICAL
               13.2.14  SERA CARE
               13.2.15  EPITOPE DIAGNOSTICS
               13.2.16  KAMIYA BIOMEDICAL COMPANY
               13.2.17  GYROS PROTEIN TECHNOLOGIES
               13.2.18  TRIVITRON HEALTHCARE
               13.2.19  INBIOS INTERNATIONAL, INC.

*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14  APPENDIX (Page No. - 418)
      14.1  INSIGHTS FROM INDUSTRY EXPERTS
      14.2  DISCUSSION GUIDE
      14.3  KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
      14.4  AVAILABLE CUSTOMIZATIONS
      14.5  RELATED REPORTS
      14.6  AUTHOR DETAILS

This study involved four major activities in estimating the current size of the immunoassay market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Immunoassay Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the immunoassay market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the immunoassay market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Immunoassay Market Size: Top-Down Approach

Immunoassay Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global immunoassay market on the basis of product, technology, specimen, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall immunoassay market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to five main regions—North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America.
  • To strategically profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as acquisitions, product launches & approvals, agreements, acquisitions, and collaborations in the immunoassay market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the RoE, RoAPAC, and RoLATAM immunoassay markets

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Immunoassay Market Size,  Share & Growth Report
Report Code
MD 4751
Published ON
Aug, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status